New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 25549122.
- Also identified by DOI 10.1038/ki.2014.354.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The best initial therapy for steroid-sensitive nephrotic syndrome (SSNS) in children is subject to ongoing debate. Systematic reviews and meta-analyses have concluded that at least 3 months and up to 7 months of treatment would reduce the number of relapses by 30%. But summarizing small underpowered studies cannot eliminate the basic flaws in design. Two well-powered randomized prospective trials now come to the opposite conclusion, and these results should impact the management of children with SSNS.
Medical subject headings
- Glucocorticoids
- Nephrotic Syndrome
- Prednisolone